Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436
 that can be given in combination with gemcitabine chemotherapy for the treatment of
 pancreatic cancer.
Inclusion Criteria:

 -  Histologically or cytologically confirmed adenocarcinoma of pancreas

 -  Locally advanced or metastatic unresectable disease

 Exclusion Criteria:

 -  No prior anti cancer chemotherapy, radiotherapy (except palliative >4 weeks prior to
 entry, endocrine or immunotherapy or use of other investigational agents;